

Date: 03/10/2024

To,
The Manager,
Listing Department,
Bombay Stock Exchange (BSE)
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.
Scrip Code: 524764

Subject: Outcome of Board Meeting held on October 3, 2024.

Dear Sir/Ma'am,

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of Nutraplus India Limited ('the Company') at its meeting held today, i.e., October 3, 2024, has approved the Audited Standalone Financial Results with the Limited Review Report for the quarter ended March 31, 2021.

The aforesaid Financial Results and Reports are enclosed herewith.

The meeting of the Board of Directors commenced at 6.30 p.m. and concluded at 8.00 p.m.

This is for your information and records.

Yours Faithfully

For Nutraplus India Limited

Mukesh Naik
Managing Director
DIN: 00412896

**RAMAN S. SHAH & ASSOCIATES
CHARTERED ACCOUNTANTS**

CA Raman S. Shah, B.Com ,F.C.A.
CA Santosh A. Sankhe, B.Com ,F.C.A.
CA Bharat C. Bhandari,B.Com ,F.C.A.



Independent Auditor's Limited review report on unaudited quarterly standalone financial results of NUTRAPLUS INDIA LIMITED for the quarter ended on 31st March,2021 and the year to results for the period from 1st April,2020 to 31st March,2021 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Regulations) Regulations, 2015, as amended.

To,
The Board of Directors,
NUTRAPLUS INDIA LIMITED
326-A, Pioneer Eyelets Mfg. Co. Ltd.
Subhash Road Jogeshwari (East),
Mumbai, 400060

1. We have reviewed the accompanying statement of unaudited quarterly standalone financial results of **Nutrapius India Limited** ("the Company") for the quarter ended 31st March, 2021, and the year-to-date results for the period from 1st April, 2020 to 31st March, 2021 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.


4. Qualified Opinion

Based on our review, except for the possible effects of the matters described in the **Basis for Qualified Limited Review Report** paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015,

Head Office :- Sam Plaza,'A' Wing,IInd Floor,H.K.Irani Road,Daharu Road (W) 401602

Branch Office:-

- 1)A-104,Ist Floor,Inder Darshan Building,Jamli Gali,Borivali(W),Mumbai(W) 400092
- 2)118-121,Ist Floor,"Harmony Plaza",Tarapur Road,Boisar,401501



**RAMAN S. SHAH & ASSOCIATES
CHARTERED ACCOUNTANTS**

CA Raman S. Shah, B.Com ,F.C.A.
CA Santosh A. Sankhe, B.Com ,F.C.A.
CA Bharat C. Bhandari,B.Com ,F.C.A.



including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. Basis for Qualified Limited Review Report

The Company has not complied with the listing requirements under the Companies Act, 2013, and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically regarding the submission of its limited review report and quarterly results within the prescribed timelines. Furthermore, certain financial data and information necessary to perform the limited review have not been provided by the Company in a timely manner, leading to significant delays in the preparation and review of the quarterly financial results. Due to these issues, our ability to perform a comprehensive review as required under the relevant standards and regulations has been significantly impaired.

6. Emphasis of Matter

We draw attention to the Statement, which describes the delay in submission of the financial results for the quarter ended 31st March, 2021, and the year-to-date results for the period from 1st April, 2020 to 31st March, 2021 due to the non-compliance with listing requirements and non-submission of information required for limited review on time. Our opinion is not modified in respect of this matter.

7. Other Matters

The statement includes the financial results for the quarter ended 31st March, 2021, and the year-to-date results for the period from 1st April, 2020 to 31st March, 2021, which is part of the required quarterly financial disclosure, and there has been a delay in submitting these results in accordance with the prescribed listing agreement rules. Our conclusion is not modified in respect of this matter.

For RAMAN S. SHAH & ASSOCIATES
CHARTERED ACCOUNTANTS
Firm Registration No.: 119891W

CA BHARAT C. BHANDARI
Partner
Membership No :- 106122
Place : Mumbai
Date : 3rd October, 2024
UDIN: 24106122BKAERS8890



Head Office :- Sam Plaza, 'A' Wing, IInd Floor, H.K. Irani Road, Dahanu Road (W) 401602
Branch Office:-
1) A-104, 1st Floor, Inder Darshan Building, Jamli Gali, Borivali (W), Mumbai (W), 400092
2) 118-121, 1st Floor, "Harmony Plaza", Tarapur Road, Boisar, 401501

NUTRAPLUS INDIA LIMITED

N-92 MIDC TARAPUR, BOISAR, DIST: PALGHAR, MAHARASHTRA

NUTRAPLUS INDIA LIMITED

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2021

(Rs. In lacs)

S.No.	Particulars	Quarter Ended			Year Ended 31st March, 2021	Year Ended 31st March, 2020
		31st March, 2021	31st December, 2020	31st March, 2020		
1	INCOME					
	Revenue from operations	1.05	-	1,375.98	1.96	10,666.81
	Other Income	5.73	3.28	6.50	9.09	14.35
	Total Income-	6.78	3.28	1,382.48	11.05	10,681.16
2	EXPENDITURE					
	Cost of Materials Consumed	-	-	791.03	-	9,626.23
	Changes in Inventories of Finished Goods & Work-in-Pro	-	-	2,358.61	-	2,028.92
	Employee Benefits Expense	0.33	2.60	215.14	6.52	733.86
	Finance Costs	17.59	6.34	143.36	45.33	743.16
	Depreciation and Amortization	-	-	120.19	-	470.14
	Other Expenses	48.15	8.21	953.44	65.67	1,861.47
	Total Expenditure	66.08	17.15	4,581.77	117.52	15,463.78
	Profit/(Loss) from operations before Exceptional & Extra Ordinary Items (1-2)	(59.30)	(13.87)	(3,199.29)	(106.48)	(4,782.62)
4	Exceptional Items	-1,783.63	-	-	-1,780.35	-
5	Profit from Ordinary Activities Before Tax (3-4)	(1,842.92)	(13.87)	(3,199.29)	(1,886.82)	-4,782.62
6	Tax Expenses					
	Current Tax	-	-	(1.77)	-	-
	Deferred Tax	-85.17	-	-	-85.17	-
	Mat Credit Entitlement	-	-	-	-	-
7	Profit/(Loss) from ordinary activities after tax (5-6)	(1,757.75)	(13.87)	(3,197.52)	(1,801.65)	(4,782.62)
8	Extraordinary Items (Net of Tax Expenses)	564.80	-	-	564.80	-
9	Net Profit/(Loss) for the period (7-8)	(2,322.55)	(13.87)	(3,197.52)	(2,366.45)	(4,782.62)
10	Other Comprehensive Income					
	Items that will not be reclassified to Statement of Profit and Loss					
	Remeasurements of net defined benefit plans	-	-	-	-	-
	Total Comprehensive income for the year (9+10)	(2,322.55)	(13.87)	(3,197.52)	(2,366.45)	(4,782.62)
	Earnings per equity share of face value of Rs. 5/- each					
	Basic and Diluted (in Rs.)	(6.81)	(0.04)	(9.38)	(7.19)	(14.03)

Notes:

- The Unaudited standalone financial results of the Company have been prepared in accordance with Indian Accounting Standard (IND AS) prescribed under section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015.
- The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 29th May, 2021. Limited Review of the same has been carried out by the Statutory Auditors of the Company in term of Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations 2015.
- The figures for the corresponding periods have been regrouped / rearranged wherever necessary for comparison purpose.
- The Company's operations fall under a single segment i.e. Active Pharmaceutical Ingredient (API).
- During the the financial year FY 21-22 under review, the Company lost all its property, plants & equipments under SARFESIA ACT, 2002, as Company was declared as Non performing Assets in FY 2019-20. Owing to the epidemic COVID'19, the bank procedure for auction of said assets was delayed, however bank could succeed.
- In FY 2020-21, the bank has taken possession all property, plant & equipment and auctioned it to recover their dues of under SARFEASI Act, 2002, hence there is no differences arises on account of deferred tax liabilities. In absence of future taxable profit, the utilisation of deferred tax asset generated in the FY 20-21 & FY 2221-22 year for Rs. 17,48,83,233/= has not been recognised in compliance of IND AS 12 as contemplated in Companies Act, 2013.
- Long term investment reported under non current investment of Rs. 4.15 Crore has been impaired and management has written off Rs. 4 Crore due to its decline in value. Hence it's carrying cost is reported as Rs. 15 Crore.
- The above results of the Company are also available on the Company's website i.e. www.nutrapiusindia.com as well as on the website of BSE i.e. www.bseindia.com

Place: Mumbai

Date: 3rd October, 2024

For & on behalf of the Board

Mukesh D. Naik
Managing Director
DIN No. : 00412896

